Our study identified that EGCG could interfere with STAT3 signaling activation in NPC cells through a novel signaling axis of miR-296/STAT3 in enhancing anoikis resistance, suggesting that miR-296/STAT3 may serve as a potential therapeutic target for metastatic NPC. This evidence concerns the gene STAT3 and nasopharyngeal carcinoma.